PCM
GPCR icon

Penserra Capital Management’s Structure Therapeutics GPCR Stock Holding History

Penserra Capital Management’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,738
Closed -$83K – 1140
2026
Q1 		$83K Buy
+1,738
New +$119K ﹤0.01% 742
2025
Q2 		– Sell
-3,411
Closed -$59K – 1070
2025
Q1 		$59K Buy
3,411
+304
+10% +$7.45K ﹤0.01% 834
2024
Q4 		$84K Buy
3,107
+135
+5% +$4.79K ﹤0.01% 879
2024
Q3 		$130K Buy
2,972
+1,384
+87% +$53.5K ﹤0.01% 753
2024
Q2 		$62K Buy
+1,588
New +$65.2K ﹤0.01% 858

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Penserra Capital Management's GPCR Position: Q2 2026 in Review

Penserra Capital Management sold out of Structure Therapeutics (GPCR) in Q2 2026, closing a stake of 1,738 shares — an estimated $83K sold.

Penserra Capital Management first reported a position in GPCR in Q2 2024 and held it in 5 quarters. The position peaked at $130K in Q3 2024. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Penserra Capital Management reported no remaining Structure Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Penserra Capital Management sold 1,738 Structure Therapeutics shares in Q2 2026, an estimated $83K.
  • Penserra Capital Management first reported a position in Structure Therapeutics in Q2 2024 and held it in 5 quarters.
  • Penserra Capital Management's Structure Therapeutics position peaked at $130K in Q3 2024.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Penserra Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.